Trial Profile
An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Intratumor Injection Mediated GPC3-targeted Chimeric Antigen Receptor T Cells in Advanced Hepatocellular Carcinoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti GPC3 chimeric antigen receptor T cell therapy Shanghai Genechem (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Shanghai Genechem
- 28 Apr 2017 New trial record